Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 12, 2001, Pages 1711-1720

  Goto, M ^a   Okamoto, Y ^a   Yamamoto, M ^a   Aki, H ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BILE ACID CONJUGATE; CARRAGEENAN; MESALAZINE; MESALAZINE PLUS CHENODEOXYCHOLIC ACID; MESALAZINE PLUS URSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING TIME; BODY WEIGHT; CECUM; CHRONIC DISEASE; COLON; COLON ULCER; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE RESPONSE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; ENTERITIS; FECES ANALYSIS; GASTROINTESTINAL TRACT; GUINEA PIG; LARGE INTESTINE; MALE; NONHUMAN; OCCULT BLOOD; SMALL INTESTINE; STOMACH; STRUCTURE ANALYSIS; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; CHENODEOXYCHOLIC ACID; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; GUINEA PIGS; MESALAMINE; URSODEOXYCHOLIC ACID;

EID: 0035678523     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011778115     Document Type: Article

References (41)

1. Animal model of human disease
2. Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid
3. Synthesis of conjugated bile acids. Bile acids and steroids 5
4. The evaluation of some red marine algae as a source of carrageenan and of its κ- and λ-components
5. Crosslinked dextran - A new capsule material for colon targeting of drugs
6. Nephrotoxic lesions from 5-aminosalicylic acid
7. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis
8. Dissolution of cholesterol gallstones by chenodeoxycholic acid
9. Role of the gut flora in toxicity and cancer
10. Studies on the intestinal flora
11. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis
12. Bile formation and hepatic plasma membrane composition in guinea-pigs and rats
13. Degradation of bile salts by human intestinal bacteria
14. pH solubility relations of chenodeoxycholic and ursodeoxycholic acids: Physical-chemical bases for dissimilar solution and membrane phenomena
15. In vivo drug release behavior in dogs from a new colon-targeted delivery system
16. Effect of ingestion of eicosapentaenoic acid ethyl ester on carrageenan-induced colitis in guinea pigs
17. Basic studies on 5-(7-hydroxy-3-O-phosphonocholyl) aminosalicylic acid for the evaluation of microbial overgrowth
18. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug del in healthy human volunteers
19. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparison of intraluminal colonic concentrations, serum values, and urinary excretion
20. 5-Aminosalicylic acid (5-ASA) induced nephrotoxicity is dose dependent in rats
21. Rapid production of ulcerative disease of the colon in newly-weaned guinea-pigs by degraded carrageenan
22. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease
23. Aqueous solubility and acidity constants of cholic, deoxycholic, chenodeoxycholic, and ursodeoxycholic acids
24. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract
25. Kinetics of 5-aminosalicylic acid after jejunal instillation in man
26. Protective effect of metronidazole in experimental ulcerative colitis
27. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea
28. Bile acid structure-activity relationship: Evaluation of bile acid lipophilicity using 1-octanol/water partition coefficient and reverse phase HPLC
29. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region
30. Effect of high and low doses of ursodeoxycholic acid on gallstone dissolution in humans
31. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis
32. The human intestinal microflora
33. The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system ("TIME CLOCK®" system)
34. 5-Amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine
35. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis
36. Sulfasalazine
37. Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs
38. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis
39. Carrageenan-induced ulceration of the large intestine in the guinea pig
40. Experimental ulcerative disease of the colon
41. Degradation of carrageenan for the experimental production of ulcers in the colon